ArticleInternational orthopaedics2025
Functional and radiographic outcomes of talar osteochondral lesions repaired with a combination of autologous bone graft, cell-free hyaluronic acid-based scaffold, bone marrow aspirate concentrate (BMAC) and fibrin glue.
Article in International orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Demographic Factors Affect the BMAC Proteome.Journal of proteome research · 2026Article
- Bone Marrow Aspirate Concentrate to Treat Ankle Osteoarthritis: A Narrative Review of Progress and Challenges.Cartilage · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of acellular hyaluronic acid matrix scaffold, BMAC, and autologous bone graft in providing biomechanical support and optimal microenvironment for OLTs treatment.
methodsA retrospective analysis of 81 ankles from 80 patients treated between 2018 and 2021 was conducted. The inclusion criteria included patients who underwent surgery for osteochondral lesions of the talus (OLTs) and received acellular hyaluronic acid matrix scaffold, bone marrow aspirate concentrate (BMAC) fibrin glue, and autologous bone graft. The exclusion criteria included prior ankle surgery, concurrent lateral instability surgery, malignancy, metabolic bone disease, or related medication. Clinical outcomes were assessed with FAOS, VAS, and SF-36 at a minimum of two years postoperatively. MRI findings were evaluated preoperatively, at six months, and 24 months postoperatively via MOCART. Subgroups were formed on the basis of age (< 45 vs. ≥45), BMI, and full weight bearing mobilization (FWBM) timing (4, 5, 6, or > 6 weeks).
resultsPostoperative FAOS and SF-36 scores significantly improved (p = 0.000), whereas VAS scores decreased (p = 0.001). Early FWBM (4th week) was associated with superior FAOS, SF-36, and MOCART scores at 24 months (p = 0.039). Underweight and healthy individuals exhibited lower VAS (p = 0.001) and higher SF-36 scores (p = 0.000) at three months, alongside higher MOCART scores at 24 months compared to overweight patients (p = 0.039).
conclusionsThis study highlights the importance of a tailored approach to optimize the microenvironment and biomechanical support in OLTs treatment. Further research is required to refine therapeutic strategies.
Indexed as
Identifiers
40266311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.